Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review

Authors
Publication date
2 July 2013
Publisher
eScholarship, University of California

Abstract

Background: Rituximab is an anti-CD20 monoclonal antibody approved for non Hodgkin lymphoma and rheumatoid arthritis. It is being considered for the treatment of MS. Objectives: To evaluate the efficacy and safety of rituximab for MS treatment. Data colle

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Sustaining member

    eScholarship - University of California

    redirect
    oaioai:escholarship.org:ark:/1303...
    Last time updated on 25/12/2021